AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18179714 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the use of the Australian Medical Sheepskin as an overlay on the mattress
Number of subjects: 750
Study 18179714 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 750
Study 16606423 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residence
Number of subjects: 1510
Study 16606423 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residence (after controlling for screening tests)
Number of subjects: 1510
Study 16606423 — intervention group
Group type: COMPARATOR
Intervention: Colorectal cancer screening rates
Number of subjects: 1510
Study 12599028 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drains
Number of subjects: 0
Study 12599028 — intervention group
Group type: COMPARATOR
Intervention: Control (no suction drains)
Number of subjects: 0
Study 10942739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafiban 5 mg
Number of subjects: 451
Study 10942739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafiban 100 mg
Number of subjects: 451
Study 10942739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafiban (all doses)
Number of subjects: 451
Study 10942739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 8769625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline administered intravenously 90 min before penicillin injection
Number of subjects: 15
Study 8769625 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pentoxifylline)
Number of subjects: 15
Study 1408297 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered treatment
Number of subjects: 87
Study 1408297 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered treatment
Number of subjects: 87
Study 1408297 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 87
Study 3532771 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate calcium of 2.5 mEq/L
Number of subjects: 20
Study 3532771 — intervention group
Group type: COMPARATOR
Intervention: Dialysate calcium of 3.5 mEq/L
Number of subjects: 20
Study 29749113 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial anti-viral therapy (valaciclovir 500-1000 mg 1-3 times daily, aciclovir 200-400 mg 1-5 times daily, topical aciclovir 2-5 times daily, topical trifluorothymidine two hourly or as needed)
Number of subjects: 296
Study 29749113 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based anti-viral therapy
Number of subjects: 296
Study 29749113 — intervention group
Group type: EXPERIMENTAL
Intervention: Indication and dose of prescribed anti-virals
Number of subjects: 296
Study 26248652 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (37.5 mg), twice daily, through last dose of oxaliplatin
Number of subjects: 50
Study 26248652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24434303 — intervention group
Group type: EXPERIMENTAL
Intervention: Training course on difficult airway management
Number of subjects: 27
Study 21208597 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release 12.5 mg/night
Number of subjects: 385
Study 21208597 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem extended-release/escitalopram
Number of subjects: 385
Study 21208597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 16134315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid cardiac 31P-MRS
Number of subjects: 20
Study 16134315 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n = 13)
Number of subjects: 20
Study 12269458 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1,450 ppmF (Colgate Great Regular Flavour)
Number of subjects: 3731
Study 12269458 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 440 ppmF (Colgate 0‐6 Gel)
Number of subjects: 3731
Study 12269458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride toothpaste provided)
Number of subjects: 3731
Study 9494149 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 935
Study 9494149 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole
Number of subjects: 935
Study 9494149 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg four times daily)
Number of subjects: 935
Study 9494149 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole (maintenance therapy)
Number of subjects: 935
Study 9494149 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg twice daily, maintenance therapy)
Number of subjects: 935
Study 9494149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maintenance therapy)
Number of subjects: 935
Study 9494149 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 935
Study 8033494 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide 50 mg
Number of subjects: 16
Study 8033494 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide 100 mg
Number of subjects: 16
Study 8033494 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide 200 mg
Number of subjects: 16
Study 2692091 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtracheal oxygen delivery (n = 22)
Number of subjects: 43
Study 2692091 — intervention group
Group type: COMPARATOR
Intervention: Usual delivery of O2 by nasal cannula or face mask (n = 21)
Number of subjects: 43
Study 789827 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymopapain
Number of subjects: 66
Study 789827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 12366873 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 800 mg in 250 ml isotonic solution
Number of subjects: 10
Study 12366873 — intervention group
Group type: COMPARATOR
Intervention: Placebo 250 ml isotonic solution
Number of subjects: 10
Study 29796649 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter + Reminder Call (RC arm)
Number of subjects: 30162
Study 29796649 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Letters + Counseling Call (CC arm)
Number of subjects: 30162
Study 29796649 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder Letter Only (LO arm)
Number of subjects: 30162
Study 29796649 — intervention group
Group type: COMPARATOR
Intervention: Incremental cost for RC arm compared to LO arm
Number of subjects: 30162
Study 29804416 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia therapy (maintained at 35±1 ℃ for 5-7 days)
Number of subjects: 62
Study 29804416 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (RT) including bloody cerebrospinal fluid drainage, spasmolysis, 3H treatment, etc.
Number of subjects: 62
Study 27909121 — intervention group
Group type: EXPERIMENTAL
Intervention: X3 HXLPE liner
Number of subjects: 15
Study 24832638 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel drug‐eluting balloons (pDEB) plus bare metal stent (BMS)
Number of subjects: 108
Study 24832638 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 108
Study 22396515 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate 50 mg/wk + placebo
Number of subjects: 139
Study 22396515 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate 125 mg/wk + placebo
Number of subjects: 139
Study 22396515 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate 300 mg/wk + placebo
Number of subjects: 139
Study 22396515 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate 600 mg/wk + placebo
Number of subjects: 139
Study 22396515 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 50 mg/wk + dutasteride
Number of subjects: 139
Study 22396515 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 125 mg/wk + dutasteride
Number of subjects: 139
Study 22396515 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 300 mg/wk + dutasteride
Number of subjects: 139
Study 22396515 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate 600 mg/wk + dutasteride
Number of subjects: 139
Study 20931531 — intervention group
Group type: EXPERIMENTAL
Intervention: MQ‐LCR technique for detecting mutations
Number of subjects: 128
Study 20931531 — intervention group
Group type: EXPERIMENTAL
Intervention: MQ‐LCR technique
Number of subjects: 128
Study 18551213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementation with adhesive bonding (group ADH) after pretreatment of the tooth and crown.
Number of subjects: 48
Study 18551213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementation with universal adhesive resin cement without pretreatment (group HYB).
Number of subjects: 48
Study 18551213 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cementation with zinc phosphate cement without pretreatment (group ZOP).
Number of subjects: 48
Study 18551213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementation techniques comparison for leakage values.
Number of subjects: 48
Study 16109551 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (ramipril starting dose of 2.5 mg/d gradually reaching 5 mg/d)
Number of subjects: 145
Study 16109551 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (irbesartan with gradual increase of doses till reaching maximum daily dose of 150 mg)
Number of subjects: 145
Study 16109551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 145
Study 12207842 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and nutrition education programme (IG)
Number of subjects: 602
Study 12207842 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 602
Study 9527092 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 48
Study 7638210 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV-6 presence in MS cases
Number of subjects: 86
Study 7638210 — intervention group
Group type: COMPARATOR
Intervention: HHV-6 presence in controls
Number of subjects: 86
Study 7638210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear staining of oligodendrocytes in MS cases
Number of subjects: 86
Study 7638210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoplasmic staining of neurons in MS cases
Number of subjects: 86
Study 7638210 — intervention group
Group type: COMPARATOR
Intervention: Neurons expressing HHV-6 in controls
Number of subjects: 86
Study 2775616 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine 250 mg fasting
Number of subjects: 6
Study 2775616 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine 250 mg after fatty meal
Number of subjects: 6
Study 2775616 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine 500 mg
Number of subjects: 6
Study 2775616 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine 1000 mg
Number of subjects: 6
Study 2775616 — intervention group
Group type: COMPARATOR
Intervention: Halofantrine 250 mg fasting vs 250 mg after fatty meal
Number of subjects: 6
Study 2775616 — intervention group
Group type: COMPARATOR
Intervention: Halofantrine 500 mg vs 1000 mg
Number of subjects: 6
Study 327746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 30
Study 327746 — intervention group
Group type: EXPERIMENTAL
Intervention: Divascan
Number of subjects: 30
Study 327746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31866194 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents sitting at the bedside during rounds
Number of subjects: 347
Study 31866194 — intervention group
Group type: COMPARATOR
Intervention: Residents standing at the bedside during rounds
Number of subjects: 347
Study 30592549 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin tregopil (IN‐105)
Number of subjects: 0
Study 30592549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28415636 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide + low-dose corticosteroid
Number of subjects: 85
Study 28415636 — intervention group
Group type: COMPARATOR
Intervention: Full-dose corticosteroid
Number of subjects: 85
Study 25608756 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 50 mg daily for 7 days
Number of subjects: 785
Study 25608756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 785
Study 23504141 — intervention group
Group type: EXPERIMENTAL
Intervention: [(99m)Tc]tilmanocept
Number of subjects: 148
Study 23504141 — intervention group
Group type: COMPARATOR
Intervention: VBD
Number of subjects: 148
Study 22696891 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg/d + zinc sulfate 10 mg/d (GZN)
Number of subjects: 40
Study 22696891 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate 0.3 mg/kg/d + placebo (GPL)
Number of subjects: 40
Study 19696423 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily for 10 days)
Number of subjects: 1749
Study 19696423 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) (5000 U every 12 hours for 10 days)
Number of subjects: 1749
Study 19696423 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 1749
Study 19696423 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 1749
Study 19696423 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin and UFH
Number of subjects: 1749
Study 16714361 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg crossing
Number of subjects: 9
Study 16714361 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 9
Study 15046215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 151
Study 15046215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 15046215 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label UDCA (after initial trial)
Number of subjects: 151
Study 11371662 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocade 25 mg
Number of subjects: 48
Study 11371662 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocade 50 mg
Number of subjects: 48
Study 11371662 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocade 100 mg
Number of subjects: 48
Study 11371662 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocade 150 mg
Number of subjects: 48
Study 11371662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9215232 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 460
Study 9215232 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 460
Study 9215232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for Simvastatin)
Number of subjects: 460
Study 9215232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for Enalapril)
Number of subjects: 460
Study 8181128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 36
Study 8181128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 36
Study 3297678 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg kg‐1 captopril pre‐treated patients
Number of subjects: 12
Study 3297678 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 12
Study 29804892 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy (HT), 60-minute sessions for 8 weeks
Number of subjects: 111
Study 29804892 — intervention group
Group type: COMPARATOR
Intervention: Social activities (control)
Number of subjects: 111
Study 29804892 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy (HT)
Number of subjects: 111
Study 27155586 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban mono-therapy
Number of subjects: 62
Study 27155586 — intervention group
Group type: COMPARATOR
Intervention: Standard-therapy with enoxaparin followed by vitamin K antagonist (VKA)
Number of subjects: 62
Study 25530057 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection at a seeking current of 0.8 mA
Number of subjects: 60
Study 25530057 — intervention group
Group type: COMPARATOR
Intervention: Injection at a seeking current of <0.5 mA
Number of subjects: 60
Study 24473591 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine - ma zi ren wan (MZRW) 7.5 g bid
Number of subjects: 120
Study 24473591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20166795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2533
Study 17634383 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 20
Study 15717632 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialyzer
Number of subjects: 48
Study 15717632 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialyzer
Number of subjects: 48
Study 14522478 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel pretreatment (300 mg before PCI)
Number of subjects: 4809
Study 10233453 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 63
Study 10233453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive pelvic muscle exercises (PME)
Number of subjects: 63
Study 10233453 — intervention group
Group type: EXPERIMENTAL
Intervention: PME plus electrical stimulation (PME+ES)
Number of subjects: 63
Study 8932971 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' attitudes toward clinical trials
Number of subjects: 99
Study 1918709 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon valvuloplasty
Number of subjects: 45
Study 1918709 — intervention group
Group type: COMPARATOR
Intervention: Closed surgical valvotomy
Number of subjects: 45
Study 6123017 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low protein diet (2.5% protein energy)
Number of subjects: 103
Study 6123017 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy intake
Number of subjects: 103
Study 6123017 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 103
Study 6123017 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 103
Study 30772298 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention including increased access to school breakfast and student-directed marketing campaigns
Number of subjects: 387
Study 30772298 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 387
Study 30772298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention effect by end of school year
Number of subjects: 387
Study 30134967 — intervention group
Group type: EXPERIMENTAL
Intervention: Atabecestat 10 mg
Number of subjects: 63
Study 30134967 — intervention group
Group type: EXPERIMENTAL
Intervention: Atabecestat 50 mg
Number of subjects: 63
Study 30134967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 30134967 — intervention group
Group type: EXPERIMENTAL
Intervention: Atabecestat 10 mg and 50 mg
Number of subjects: 63
Study 30134967 — intervention group
Group type: EXPERIMENTAL
Intervention: Atabecestat (both doses)
Number of subjects: 63
Study 27998899 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed open‐glottis pushing
Number of subjects: 250
Study 27998899 — intervention group
Group type: COMPARATOR
Intervention: Directed closed‐glottis pushing (Valsalva)
Number of subjects: 250
Study 24813828 — intervention group
Group type: EXPERIMENTAL
Intervention: SOMNOwatch plus EEG
Number of subjects: 13
Study 24813828 — intervention group
Group type: EXPERIMENTAL
Intervention: SOMNOwatch plus EEG (DOMINO Light)
Number of subjects: 13
Study 24813828 — intervention group
Group type: COMPARATOR
Intervention: Classical EEG amplifier (NeuroScan system)
Number of subjects: 13
Study 22805313 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Korean red ginseng (3 g/day)
Number of subjects: 57
Study 22805313 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Korean red ginseng (6 g/day)
Number of subjects: 57
Study 22805313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 22805313 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG supplementation (both doses)
Number of subjects: 57
Study 19194969 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol 25 mg, six times/day for thirteen doses
Number of subjects: 40
Study 19194969 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol 50 mg, six times/day for thirteen doses
Number of subjects: 40
Study 19194969 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol 100 mg, six times/day for thirteen doses
Number of subjects: 40
Study 19194969 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol 150 mg, six times/day for thirteen doses
Number of subjects: 40
Study 19194969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17447863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention group (received one tailored letter on all behaviors)
Number of subjects: 0
Study 17447863 — intervention group
Group type: COMPARATOR
Intervention: Control intervention group (received one general information letter on all behaviors)
Number of subjects: 0
Study 17447863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention group
Number of subjects: 0
Study 15587571 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 25
Study 15587571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11483803 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit intervention including an information package, discount coupons, and specific instruction regarding home safety measures.
Number of subjects: 100
Study 11483803 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group (control).
Number of subjects: 100
Study 9951927 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant locoregional chemoimmunotherapy (Gemcitabine 1 gm/m2, Carboplatin 200 mg/m2, Mitoxantrone 0.2 g/kg bw, IL-2, gamma-IFN)
Number of subjects: 512
Study 9951927 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control group)
Number of subjects: 512
Study 7924365 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterally fed patients
Number of subjects: 30
Study 7924365 — intervention group
Group type: COMPARATOR
Intervention: Nonenterally fed patients
Number of subjects: 30